News

JERSEY, Channel Islands, 1 May, 2020 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced that it has completed the process for declaring conformity to the essential requirements of the In

JERSEY, Channel Islands, April 27, 2020 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported very strong final study performance data for its SARS-CoV-2 antibody test. The Company expects to complete the CE marking process and the

JERSEY, Channel Islands, April 21, 2020 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported positive performance data for its SARS-CoV-2 antibody test. Based on these results, under applicable regulations, the Company can now offer the MosaiQ

Mass diagnosis ‘available now’ A Swiss medical diagnostics company has said it is able to ship tens of thousands of coronavirus antibody tests from early next week. Quotient has been developing the test in Edinburgh and Switzerland and said it

Experts say antibody testing will play a crucial role in easing coronavirus lockdowns around the world and reviving economies. “If you have antibody tests you can identify those who are already immune and can go back safely to work and

Quotient warns global shortages of critical components could hamper efforts To read the full article, visit: Financial Times

JERSEY, Channel Islands, April 06, 2020 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the completion of the development phase of a microarray based SARS-CoV-2 (COVID-19) antibody test for the

JERSEY, Channel Islands, Feb. 14, 2020 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced that it has received the Conformité Européene (CE) Mark approval for the Initial Serological Disease Screening (SDS) Microarray. “We are very

C’est une revolution dans l’univers de l’analyse de sang. Quotient, une société basée à Eysins (VD), aux portes de Nyon, met sur le marché une nouvelle technique qui permet d’obtenir des résultats complets d’un échantillon avec une grande rapidité. Ces